Currently, diabetes mellitus (DM) and its complications are among the first three causes of mortality, superseded only by cardiovascular and oncologic diseases. Notably, DM tends to be currently ranked the second cause of mortality, as the myocardial infarction complicated by cardiac failure often comes as a complication of diabetes mellitus. The RF diabetes mellitus state registry for 2010 enlists 3.1 million of diabetic patients, of which 2.8 million patients suffer from type 2 DM. Numerous studies, inclusive of those conducted by WHO, demonstrate that the DM issue appears to be even more serious, as, in fact, the number of diabetes mellitus patients in Russia totals 9.6 million people, of which around 8.5 million suffer from type 2 DM. Not all of these people are aware of their DM diagnosis, or are officially registered as such.
Having been driven by the demand of physicians and DM patients, one of the leading Russian drug manufacturer Akrikhin has brought to market a new product for treatment of type 2 diabetes mellitus named Diamerid containing glimepiride as an active substance. It is glimepiride which is a drug of choice in patients with coronary heart disease, initial deterioration of renal function and patients prone to blood glucose lowering response at the backdrop of administration of other drugs stimulating insulin production. The complete drug development cycle, from the design stage to drug manufacturing, is carried out by Akrikhin.
Diamerid is the only drug, amongst all available on the market glimepiride generics, which is produced in all possible dosages for this drug, namely, 1 mg, 2 mg, 3 mg and 4 mg, and, hence, enabling physicians to prescribe the most pathogenetically justified, efficacious and safe treatment. The use of the Russian-made drug is entirely justified from an economic standpoint, and, given its absolute bioequivalence to the original product, the Russian-made generic is much more affordable.
According to the analytical agency “Pharmexpert”, based on 2010 results the market share of Akrikhin in the glucose-lowering products’ segment is 4%, whereas the market share of all Russian manufacturers does not exceed 8% (in monetary value (USD), and not counting insulins), leaving 94% of the glucose-lowering products’ segment to the imported products. Launch of an affordable and efficacious anti-diabetic drug of the Russian-based manufacturer expands treatment options for patients with type 2 diabetes mellitus.
Akrikhin is committed to active development of its anti-diabetic drugs’ portfolio. Diamerid has become a number six product in the company’s line of glucose-reducing medicines. All anti-diabetic drugs have been developed by the R&D Center of Akrikhin.
Diamerid has become the number 8 product brought to market by Akrikhin in 2011, along with the anti-tuberculosis and dermatological products. All new company products belong to the key pharmacotherapeutic classes which are in the focus of company’s attention.
Information about Akrikhin:
Akrikhin is one of the leading Russian pharmaceutical companies manufacturing high-quality medicinal products, and ranks among Russia’s TOP 5 largest local pharmaceutical producers in terms of sales volume on the Russian pharmaceutical market.
Akrikhinwasfoundedin 1936. The company product portfolio includes over 150 drugs which belong to the main pharmacotherapeutic groups, such as cardiology, neurology, pediatrics, gynecology, dermatology, etc.
Akrikhin manufactures a broad spectrum of socially significant medicines, and is one of the largest Russian manufacturers of the vitally important medicines, as well as drugs for treatment of tuberculosis and diabetes.
Since 2007, the strategic partner of Akrikhin on the Russian pharmaceutical market is Polpharma. The strategic partnership surmises close collaboration between the companies in the field of research and development, manufacturing and marketing of products.
At the end of 2010, Akrikhin joined the ranks of TOP 3 of the most reputable and recognized Russian pharmaceutical producers, according to the “Rating of influence of Russian pharmaceutical market participants” (cited by “Pharmexpert”).
For additional information, please contact Julia Zaika, public relations manager of Akrikhin.
Phone: 8 (495) 721-36-97.
Mobile: 8 (916) 839-95-71.
E-mail: j.zaika@akrikhin.ru